

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 14, 2025

PE anti-mouse IFN-?

RRID:AB_315401

Type: Antibody

Proper Citation

(BioLegend Cat# 505807, RRID:AB_315401)

Antibody Information

URL: http://antibodyregistry.org/AB_315401

Proper Citation: (BioLegend Cat# 505807, RRID:AB_315401)

Target Antigen: IFN-gamma

Host Organism: rat

Clonality: monoclonal

Comments: Applications: ICFC

Antibody Name: PE anti-mouse IFN-?

Description: This monoclonal targets IFN-gamma

Target Organism: mouse

Clone ID: Clone XMG1.2

Antibody ID: AB_315401

Vendor: BioLegend

Catalog Number: 505807

Alternative Catalog Numbers: 505808

Record Creation Time: 20241016T222356+0000

Record Last Update: 20241016T224824+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse IFN- γ .

No alerts have been found for PE anti-mouse IFN- γ .

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 28 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Strobl K, et al. (2024) JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia. *EMBO molecular medicine*, 16(12), 3142.

Shu G, et al. (2024) PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma. *Cancer research*, 84(10), 1659.

Joshi S, et al. (2024) Tim4 enables large peritoneal macrophages to cross-present tumor antigens at early stages of tumorigenesis. *Cell reports*, 43(4), 114096.

Gour N, et al. (2024) A GPCR-neuropeptide axis dampens hyperactive neutrophils by promoting an alternative-like polarization during bacterial infection. *Immunity*, 57(2), 333.

Benguigui M, et al. (2024) Interferon-stimulated neutrophils as a predictor of immunotherapy response. *Cancer cell*, 42(2), 253.

Feng S, et al. (2024) Blockage of L2HGDH-mediated S-2HG catabolism orchestrates macrophage polarization to elicit antitumor immunity. *Cell reports*, 43(6), 114300.

Yuan L, et al. (2024) A broad-spectrum multiepitope vaccine against seasonal influenza A and B viruses in mice. *EBioMedicine*, 106, 105269.

Sekiya T, et al. (2024) Tonic TCR and IL-1 β signaling mediate phenotypic alterations of naive CD4⁺ T cells. *Cell reports*, 43(3), 113954.

Li Q, et al. (2024) Biomineralization-inspired synthesis of autologous cancer vaccines for personalized metallo-immunotherapy. *iScience*, 27(7), 110189.

Abadie K, et al. (2024) Reversible, tunable epigenetic silencing of TCF1 generates flexibility in the T cell memory decision. *Immunity*, 57(2), 271.

Seike K, et al. (2023) Ambient oxygen levels regulate intestinal dysbiosis and GVHD severity

after allogeneic stem cell transplantation. *Immunity*, 56(2), 353.

Danielli S, et al. (2023) The ion channel CALHM6 controls bacterial infection-induced cellular cross-talk at the immunological synapse. *The EMBO journal*, 42(7), e111450.

Tripodi L, et al. (2023) Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma. *iScience*, 26(10), 107668.

Jiang SS, et al. (2023) Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. *Cell host & microbe*, 31(5), 781.

Foskolou IP, et al. (2023) The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic T cell function. *Cell reports*, 42(9), 113013.

Miyauchi S, et al. (2023) Reprogramming of tumor-associated macrophages via NEDD4-mediated CSF1R degradation by targeting USP18. *Cell reports*, 42(12), 113560.

Yang JF, et al. (2023) Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8⁺ T cell metabolic fitness and function in tumors. *Science immunology*, 8(87), eabq2424.

Mirlekar B, et al. (2022) Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. *Cell reports. Medicine*, 3(9), 100744.

Shen JZ, et al. (2022) A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells. *Molecular cell*, 82(6), 1123.

Ma C, et al. (2022) Platelets control liver tumor growth through P2Y₁₂-dependent CD40L release in NAFLD. *Cancer cell*, 40(9), 986.